# CVRx, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/CVRx, Inc.).

## Overview

CVRx, Inc. develops and commercializes Barostim, an implantable neuromodulation therapy used to treat heart failure patients, particularly those with HFrEF and a narrow QRS complex. The company sells primarily to hospitals, with U.S. commercialization handled through a direct sales force and European sales supported by direct teams in Germany and distributors in selected countries. Its business is built around physician education, clinical adoption, reimbursement support, and patient identification, rather than high-volume consumer sales. CVRx is still in an expansion phase, with management focused on growing U.S. commercial coverage and broadening the clinical use of Barostim over time. The company also invests in product development to improve Barostim and explore additional cardiovascular indications such as hypertension and arrhythmias.

## Products & services

• Barostim implantable therapy for heart failure
• Hospital-based sales and clinical support
• Physician education and training programs
• Reimbursement assistance and patient qualification support
• Direct-to-consumer awareness and referral education

- **Implantable neuromodulation therapy** (100%) — Barostim is the core implantable device therapy used to treat selected heart failure patients.
- **Commercial support and adoption services** (0%) — Clinical education, reimbursement support, and patient identification services that help hospitals adopt Barostim.

- Barostim implantable therapy for heart failure
- Hospital-based sales and clinical support
- Physician education and training programs
- Reimbursement assistance and patient qualification support
- Direct-to-consumer awareness and referral education

## Customers

CVRx sells primarily to hospitals and implanting centers that treat heart failure patients and perform Barostim procedures. The company’s commercial focus is on high-volume cardiology centers, where adoption can scale through physician training and referral networks. Key users and influencers include heart failure specialists, interventional and general cardiologists, advanced practice providers, electrophysiologists, vascular surgeons, and cardiothoracic surgeons. In the U.S., reimbursement from CMS is an important part of the buying decision because it affects hospital willingness to adopt the therapy and patient access. In Europe, hospitals and distributors are the main commercial counterparties, with local pricing and channel mix influencing uptake.

- **U.S. hospitals and active implanting centers** (primary) — Buy Barostim for commercial implantation in heart failure patients and rely on reimbursement support and clinical training.
- **European hospitals** (primary) — Purchase Barostim through direct sales in Germany and distributors in other European countries, with adoption shaped by local pricing and regulatory requirements.
- **Physicians and clinical specialists** (primary) — Do not buy the device directly, but they are critical decision-makers who evaluate clinical evidence and determine patient eligibility.
- **Distributors** (secondary) — Resell Barostim in selected European markets and help extend geographic reach where CVRx does not sell directly.

- Hospitals and implanting centers that purchase Barostim for HF procedures
- Heart failure specialists who identify eligible patients and drive adoption
- Cardiologists and electrophysiologists who influence therapy selection
- Vascular and cardiothoracic surgeons involved in implantation workflows
- Distributors in parts of Europe that resell into local hospital accounts
- Patients with HFrEF who benefit indirectly through physician referral and reimbursement

## Geography

CVRx generates most of its revenue in the United States, where it has a direct sales organization and where management expects to focus most commercial effort in the near term. The company also sells in Europe, with direct operations in Germany and distributor coverage in Austria, Spain, and other European countries. In the year ended December 31, 2025, the U.S. accounted for $51.9 million of revenue and Europe for $4.8 million, showing a strong domestic concentration. Geography matters because U.S. reimbursement through CMS supports adoption, while European sales are more sensitive to country-level pricing, channel mix, and foreign exchange. The company’s international exposure is therefore smaller but more operationally complex than its U.S. business.

- **United States** (91.6%) — 2025 revenue by geography from annual report
- **Europe** (8.4%) — 2025 revenue by geography from annual report; includes Germany and other select European countries

- United States is the core market and the main source of revenue
- Germany is the key European direct-sales market
- Austria, Spain, and other European countries are served through distributors
- U.S. reimbursement by CMS supports hospital adoption and access
- European revenue is affected by local pricing, channel mix, and FX
- Management expects U.S. commercial expansion to drive near-term growth

## Strategy

CVRx’s near-term strategy is to expand its U.S. direct sales force and deepen penetration at high-volume cardiology centers. The company is also investing in physician education, KOL development, referral network education, and direct-to-consumer marketing to improve awareness and conversion. On the product side, management is focused on continued technological advancement of Barostim while maintaining the current commercial focus on HFrEF. Longer term, CVRx wants to broaden Barostim’s addressable market by pursuing additional indications such as other forms of heart failure, hypertension, and arrhythmias, which would require further clinical evidence and regulatory approvals. This strategy is designed to increase procedure volume, strengthen reimbursement-supported adoption, and reduce dependence on a single indication over time.

- **Expand U.S. commercial organization** (short-term) — The U.S. is the main revenue engine, and more sales territories and active implanting centers should increase Barostim adoption.
- **Increase physician and patient awareness** (short-term) — Barostim adoption depends on physician confidence, referral flow, and patient identification in a specialized treatment pathway.
- **Broaden clinical and regulatory scope** (medium-term) — New indications could expand the addressable market and reduce reliance on a single heart-failure segment.

- Expand U.S. direct sales coverage and add more territories
- Target high-volume cardiology centers to improve procedure adoption
- Invest in physician education, KOLs, and referral network development
- Use direct-to-consumer marketing to increase patient awareness
- Advance Barostim technology through ongoing R&D
- Pursue broader indications beyond HFrEF over the long term

## Risks

CVRx faces execution risk because its business depends on building a specialized sales organization and convincing physicians to adopt a relatively novel implantable therapy. The company also remains loss-making, so continued commercialization and R&D spending must be funded before the business reaches scale. Reimbursement and healthcare policy are important risks because changes in coverage or payer economics could slow hospital adoption or reduce procedure profitability. Internationally, the company is exposed to foreign regulatory requirements, especially in Europe, where MDR compliance and local market rules can affect commercialization. More broadly, competition from other device-based heart-failure therapies, clinical trial outcomes, and foreign exchange volatility can all affect growth and margins.

- **Sustained operating losses** [high] — The company expects continued sales, marketing, regulatory, and R&D spending before reaching scale, which can pressure liquidity and investor confidence.
- **Reimbursement and healthcare reform** [high] — Barostim adoption depends on hospital reimbursement economics; lower coverage or cost containment could reduce procedure volumes.
- **Commercial execution and sales force build-out** [high] — Growth depends on hiring, training, and retaining specialized medical device sales personnel and expanding active implanting centers.
- **Regulatory compliance in Europe** [medium] — Failure to comply with foreign device regulations, including MDR, could restrict sales or increase compliance costs.
- **Clinical and competitive risk** [high] — Barostim competes with other device-based therapies, and future indications require successful clinical trials and regulatory approvals.

- Ongoing losses and cash burn while the company scales commercialization
- Dependence on physician adoption and clinical evidence for Barostim
- Reimbursement risk if CMS or other payers change coverage or economics
- Sales force hiring and retention risk in a competitive medical device labor market
- Regulatory risk in Europe and other foreign jurisdictions
- Competition from other device-based therapies for HFrEF
- Foreign exchange volatility affecting international revenue

## Accounting

CVRx’s reported results are sensitive to revenue timing because sales are concentrated in hospital implant procedures and international distributor channels, which can create quarter-to-quarter variability. The company’s revenue mix between the U.S. and Europe also matters because European sales can fluctuate with channel mix, local pricing, and foreign currency exchange rates. As a medical device company with ongoing commercialization and development spending, management must estimate inventory obsolescence, manufacturing overhead absorption, and other cost-of-goods components that affect gross margin. The company also notes it is an emerging growth company using the extended transition period for new accounting standards, which can reduce comparability with larger public peers. Investors should also watch stock-based compensation and other judgmental estimates that affect operating expenses and reported losses.

- **Revenue recognition and channel timing** — Affects revenue timing and comparability across quarters
- **Inventory obsolescence and manufacturing overhead** — Affects cost of goods sold and gross margin
- **Foreign currency translation** — Affects international revenue and margins
- **Stock-based compensation** — Affects operating expenses and earnings
- **Emerging growth company accounting election** — Affects comparability of reported financials

- Revenue timing can vary with hospital implant activity and distributor shipments
- U.S. versus Europe mix affects reported revenue and gross margin
- Foreign currency exchange rates can change the value of international sales
- Inventory obsolescence and manufacturing overhead estimates affect cost of goods sold
- Stock-based compensation is a meaningful judgmental expense line
- Emerging growth company accounting can reduce comparability with peers

---

*Last updated: 2026-04-28T14:24:55.492784+00:00*